EyeFocus Eye Care Innovation Conference

31 January 2017, London, UK.
EyeFocus is holding a one day conference about eye-care innovation to end the second EyeFocus program. The conference is instead of the traditional demo day, and will go beyond startups pitching to investors, instead presenting the ecosystem EyeFocus has built in eye-care innovation.

The conference will bring together thought leaders from across eye-care, innovation, and tech. The day will feature keynote talks, discussion panels, and short pitches from a broad range of the companies in the EyeFocus program, from startups to developed businesses.

The aim of the day is to share the built ecosystem, and the knowledge clustered around EyeFocus, and to promote innovation in eye-care. The day will be a mix of networking, education, and information for people working in eye-care, health tech, and startups.

EyeFocus Eye Care Innovation Conference is sponsored by Bayer, and has partnered with the world famous Royal National Institute for Blind People (RNIB), and Royal Academy of Engineering (RAENG) to bring thought leaders from across the eye-care spectrum together for a unique event in the centre of London.

For further information and to buy tickets, please visit:
https://www.eventbrite.com/e/eyefocus-conference-tickets-29612858858?aff=eHealthNews&afu=197085922377

About EyeFocus
EyeFocus is the world's first eye-care accelerator and innovation program. We run events around the world to bring together opinion leaders and practitioners in eye-care innovation to leave our ecosystem better connected, and to focus academics, innovators, and practitioners on thinking about how to create new products and solutions for people who are blind or visually impaired.

EyeFocus is a project of Newsquare Innovation. Newsquare develops programs to create connected ecosystems in healthcare innovation, accelerating early stage companies, and building bridges between academia, industry, entrepreneurs, and healthcare.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...